QGEN vs NEOG

For growth investors, Qiagen N.

V. (QGEN) is the stronger pick with 5. 7% revenue growth year-over-year, versus -3. 2% for Neogen Corporation (NEOG). Qiagen N. V. (QGEN) offers the better valuation at 16. 9x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Qiagen N. V. (QGEN) a "Hold" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Qiagen N.

V. is actually cheaper at 13. 8x.

Over the past 5 years, Qiagen N.

V. (QGEN) delivered a total return of -21. 6%, compared to -80. 6% for Neogen Corporation (NEOG). Over 10 years, the gap is even starker: QGEN returned +70. 4% versus NEOG's -49. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Qiagen N.

V. (QGEN) is the lower-risk stock at 0. 42β versus Neogen Corporation's 1. 83β — meaning NEOG is approximately 338% more volatile than QGEN relative to the S&P 500. On balance sheet safety, Qiagen N. V. (QGEN) carries a lower debt/equity ratio of 44% versus 44% for Neogen Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Qiagen N.

V. (QGEN) is pulling ahead at 5. 7% versus -3. 2% for Neogen Corporation (NEOG). On earnings-per-share growth, the picture is similar: Qiagen N. V. grew EPS 436. 8% year-over-year, compared to -114. 6% for Neogen Corporation. Over a 3-year CAGR, NEOG leads at 19. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Qiagen N.

V. (QGEN) is the more profitable company, earning 20. 3% net margin versus -122. 1% for Neogen Corporation — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QGEN leads at 24. 9% versus 1. 1% for NEOG. At the gross margin level — before operating expenses — QGEN leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Qiagen N.

V. (QGEN) trades at 13. 8x forward P/E versus 25. 7x for Neogen Corporation — 11. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for QGEN: 37. 8% to $47. 50.

In this comparison, QGEN (0.

8% yield) pays a dividend. NEOG does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Qiagen N.

V. (QGEN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 42), 0. 8% yield). Neogen Corporation (NEOG) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (QGEN: +70. 4%, NEOG: -49. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: QGEN is a small-cap deep-value stock; NEOG is a small-cap quality compounder stock. QGEN pays a dividend while NEOG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.